Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Dr. Reddy’s Custom Pharmaceutical Services business expands its manufacturing operations in MirThe Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories Ltd. today announced expansion in the areas of activated mPEG manufacturing and in the development and manufacture of NCE (New Chemical Entities) APIs
By: Dr. Reddy's Laboratories The expansion puts Dr. Reddy's at the forefront of activated mPEG manufacturing and will enable manufacture of its PEGtechTM range at commercial metric tonne scale quantities and beyond in a fully cGMP environment. Equipped with state-of-the- Commenting on the development, Dr. R. Ananthanarayanan, President-Pharmaceutical Services and Active Ingredients business, Dr. Reddy’s said, “This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing” Dr. Reddy’s has eight API manufacturing facilities (Six FDA-approved plants in India, One FDA-approved plant in Mexico and One FDA-approved plant in Mirfield, UK) worldwide, which help the CPS business to provide its customers with multiple site options. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|